Efficacy and Safety of Omeprazole for the Treatment of Acid Peptic Disorders: A Systematic Review and Meta-Analysis

Table 1

Study population characteristics of 31 included trials (41 treatment arms) for the treatment of acid peptic disease (APD).

Study arm	Reference	Type APD	Nos.	Setting	Age (yrs)	Country	1° outcome	Ome dose	Duration (wks)	Control	Control dose	Attrition (%)
1a	Armstrong 2004−20 mgE	NERD	2645	Out	18–83	10 mixed	No heartburn	20	4	ESO20	20	Nr
1b	Armstrong 2004−40 mgE	—			—		—	20	4	ESO40	40	—
2	Bardhan 2001	EO	327	Out	≥18	UK, Ir, SA	Symp relief	20	4^a	PAN20	20	19
3	Bate 1996	NERD	209	Nr	18–80	UK, Ir	No heartburn	20	4	Placebo	0	20
4a	Carlsson 1998−10 mgO	NERD	261	Nr	18–80	Au, H, N, UK	Symp relief	10	4	Placebo	0	6
4b	Carlsson 1998−20 mgO	—			—		—	20	4	Placebo	0	—
5a	Catalano 1999−40 mgP	DU	243	Nr	18–75	Italy	Ulcer healed	40	1.5	PAN40	40	8
5b	Catalano 1999−80 mgP	—			—		—	40	1.5	PAN80	80	—
6	Catalano 2000	DU	172	Nr	19-20	Italy	Ulcer healed	40	4	PAN80	80	21
7	Chang 1995	DU	111	Out	21–75	Taiwan	Ulcer healed	20	4	LAN30	30	4
8	Chen C 2017	DU	80	Nr	20–60	China	Ulcer healed	20	4	ILA10	10	Nr
9	Chen S 2017	DU	60	Nr	18–71	China	Ulcer healed	20	8	PAN40	40	Nr
10	Dekkers C 1999	EO	202	Nr	≥18	10 Euro	Erosion healed	20	4^a	RAB20	20	5
11	Ekstrom 1995	DU	279	Nr	18–80	Sweden	Ulcer healed	20	4	LAN30	30	16
12a	Ho K 2009-5 mgI	DU/GU	518	Nr	18–80	5 Asian	Ulcer healed	20	4	ILA5	5	32
12b	Ho 2009−10 mgI	—			—		—	20	4	ILA10	10	—
13	Huang 2010	DU	120	Mixed	20–65	Mongolia	Ulcer healed	20	4	PAN40	40	Nr
14a	Kahrilas 2000−20 mgE	EO	1960	Nr	Adults	USA	Erosion healed	20	4^a	ESO20	20	8
14b	Kahrilas 2000−40 mgE	—			—		—	20	4	ESO40	40	—
15	Li 2010	DU/PU	100	Nr	16–70	China	Ulcer healed	20	4	PAN40	40	0
16	Liao 2015	DU	80	Out	22–76	China	Ulcer healed	20	4	ILA10	10	Nr
17a	Lind 1997−10 mgO	NERD	509	Nr	≥18	Sw, Den	No heartburn	10	4	Placebo	0	5
17b	Lind 1997−20 mgO	—			—		—	20	4	Placebo	0	—
18	Mossner 1995	EO	286	Nr	≥18	Germany	Erosion healed	20	4^a	PAN40	40	1
19	Pei 1995	DU	72	Nr	21–70	China	Ulcer healed	20	4	LAN30	30	Nr
20	Petite 1993	DU	144	Mixed	≥18	France	Ulcer healed	20	2^a	LAN30	30	6
21	Rehner 1995	DU	286	Nr	≥18	Germany	Ulcer healed	20	2^a	PAN40	40	3
22a	Richter 2000−10 mgO	NERD	359	Nr	≥18	USA	No heartburn	10	4	Placebo	0	1
22b	Richter 2000−20 mgO	—			—			20	4	Placebo	0	—
23a	Uemura 2008−10 mgO	NERD	284	Nr	≥20	Japan	No heartburn	10	4	Placebo	0	5
23b	Uemura 2008−20 mgO	—			—			20	4	Placebo	0	—
24	Wang L 2012	DU	494	Nr	18–65	China	Ulcer healed	20	4	ILA10	10	5
25	Watson 1997	NERD	19	Out	22–79	Ir	Symp better	40	4	Placebo	0	16
26	Xiao 1997	GU/DU	188	Nr	16–68	China	Ulcer healed	20	4–6^b	LAN30	30	Nr
27	Xu 2006	DU	68	Out	15–78	China	Ulcer healed	20	4	RAB20	20	Nr
28	You QX 2006	DU	72	Out	18–75	China	Ulcer healed	20	4	RAB20	20	Nr
29	Zhao 2013	DU	76	Nr	29–69	China	Ulcer healed	20	4	PAN40	40	Nr
30a	Zheng 2009−30 mgL	EO	275	Nr	36–85	China	Erosion healed	20	8	LAN30	30	4
30b	Zheng 2009−40 mgP	—			—			20	8	PAN40	40	—
30c	Zheng 2009−40 mgE	—			—			20	8	ESO40	40	—
31	Zou 2012	DU	40	Nr	19–62	China	Ulcer healed	20	4	PAN40	40	Nr

Notes. ^aDuration, patients unresponsive to initial duration of treatment had extended 2–4 weeks of treatment (outcome was determined at original time of treatment not extended time); ^b4 weeks if DU and 6 weeks if GU. dy, days; DU, duodenal ulcer; EO, erosive oesophagitis; ESO, esomeprazole; GU, gastric ulcer; ILA, ilaprazole; LAN, lansoprazole; NERD, nonerosive reflux disease; Nr, not reported in paper; mixed, inpatients and outpatients; OME, omeprazole; out, outpatients; PAN, pantoprazole; PU, peptic ulcer; RAB, rabeprazole; symp, symptoms; wks, weeks; yrs, years. Countries: Asian, varied Asian countries; Au, Australia; Den, Denmark; Euro, varied European countries; H, Holland; Ir, Ireland; SA, South Africa; Sw, Sweden; UK, United Kingdom, US, United States of America; mixed, mixed geographic areas.